RemeGen Co (HKSE:09995) Dividends per Share : HK$0.00 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Dividends per Share?

RemeGen Co's dividends per share for the three months ended in Dec. 2023 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, RemeGen Co's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

RemeGen Co Dividends per Share Historical Data

The historical data trend for RemeGen Co's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Dividends per Share Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of RemeGen Co's Dividends per Share

For the Biotechnology subindustry, RemeGen Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Dividend Yield % falls into.

RemeGen Co Dividends per Share Calculation

Dividends paid to per common share.

RemeGen Co (HKSE:09995) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

RemeGen Co's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

RemeGen Co Dividends per Share Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines